Considering several kinds of treatments for human papillomavirus anal infection, the topical immune response modifier imiquimod is an option. An imidazoquinoline derivate, imiquimod is a chemotherapic drug and an immune stimulator with antitumoral and antiviral action. The medication is used at home, by patients, three times a week, in alternated nights, for eight to 16 weeks. Side-effects are common, but well tolerated. This drug reaches from 74 to 84% of remission, although from 25 to 77% are complete. There are lower complete remission and higher recurrence in immune compromised patients. Studies with more patients for better evaluation of this medication efficiency are needed, including those about recurrences and time free from new lesions.
Papillomavirus infections; Immunotherapy; Condylomata Acuminata; Immunomodulation